FDA approves Novo Nordisks' hemophilia drug: 3 things to know

The Food and Drug Administration on Wednesday approved Novo Nordisk's new hemophilia treatment, Rebinyn.

Here are three things to know.

1. Rebinyn is intended to treat adults and children with hemophilia B, an inherited blood disorder that causes prolonged or spontaneous bleeding.
   
   

2. Patients may take the drug when experiencing a bleeding episode or prior to surgery so clinicians can better manage bleeding during the procedure.
   
   

3. Novo Nordisk plans to release Rebinyn in the first half of 2018.
   
   

More articles on supply chain:

Amgen sues FDA over drug exclusivity rights: 5 things to know
Appellate court: Fairvew Health's medical device telemarketing does not violate robocall rules
Drug execs anticipate Trump's drug pricing plans: 4 things to know